Tumor and immune cell imaging based on pd-l1 expression
AssigneeThe Johns Hopkins University
InventorsSridhar Nimmagadda, Martin Pomper, Samit Chatterjee, Wojciech Lesniak, Dhiraj Kumar
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter provides compositions, kits, and methods comprising imaging agents that can detect Programmed Death Ligand 1 (PD-L1). The presently disclosed imaging agents can be used to detect diseases and disorders, such as cancer, infection, and inflammation, in a subject.
Claims53
An imaging agent comprising a conjugate of a peptide having a binding specificity for programmed death ligand 1 (PD-L1) and a reporting moiety, and optionally a linker, wherein the linker, when present connects the peptide and the reporting moiety, and when the linker is absent, the reporting moiety is attached directly to the peptide through a primary amine of an amino acid of the peptide.
Dependencies are inferred from the claim text.